Bluebirdbio stock.

Bluebird bio Inc’s current trading price is -47.49% away from its 52-week high, while its distance from the 52-week low is 78.77%. The stock’s price range over this period has fluctuated between $2.52 and $8.58. The company, operating within the financial sector, had a trading volume of approximately 2.61 million for the day, which was ...

Bluebirdbio stock. Things To Know About Bluebirdbio stock.

Nov 24, 2023 · The low in the last 52 weeks of bluebird bio stock was 2.52. According to the current price, bluebird bio is 155.56% away from the 52-week low. What was the 52-week high for bluebird bio stock? Earnings for bluebird bio are expected to decrease in the coming year, from ($1.81) to ($1.84) per share. bluebird bio has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 3rd, 2024 based off prior year's report dates. Read More.Summary. bluebird works as a biotech company developing curative gene therapies to save lives. Concerns over its cash runway and clinical trials are overblown, with the stock near all-time lows ...Aug 28, 2023 · Bluebird Bio (BLUE 11.52%), a leader in gene therapy, could be a great pick for growth investors.This company has two gene therapies that the U.S. Food and Drug Administration (FDA) has approved ... Apple Inc. Common Stock. $191.6541 +1.9641 +1.04%. bluebird bio, Inc. Common Stock (BLUE) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market …

On Tuesday morning, gene therapy specialist bluebird bio ( BLUE 2.64%) announced the temporary suspension of two of its clinical trials for LentiGlobin, an experimental gene therapy for sickle ...

Let's look at Bluebird Bio (BLUE 2.64%). Per Wall Street's analysts, its shares could rise 118% by this time next year despite losing 51% of their value so far in 2023.Bluebird Bio ( BLUE 2.64%) had quite a ride with their stock on Tuesday. Following the gene-editing specialist's release of its latest quarterly results, its shares climbed to a more than 7% gain ...

Real time Bluebird Bio (BLUE) stock price quote, stock graph, news & analysis. Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.12 thg 7, 2023 ... Concerns over its cash runway and clinical trials are overblown, with the stock near all-time lows. ... bluebird bio's product pipeline (www.Find real-time BLUE - bluebird bio Inc stock quotes, company profile, news and forecasts from CNN Business.

18 thg 6, 2019 ... Bluebird Bio stock dipped Tuesday after an analyst noted manufacturing hiccups will prevent the biotech company from selling its gene ...

BofA Securities has a $10 target price on Bluebird Bio stock. The consensus target is lower at $7.30. The stock closed on Friday at $4.05 up over 15%. Commscope.

Shares of Bluebird Bio ( BLUE 0.61%) were sinking 10.4% this week as of the market close on Thursday, according to data from S&P Global Market Intelligence. The decline came after the company [email protected]. Investor Contacts. Courtney O’Leary. Investor Relations (978) 621-7347. [email protected]. stock quote stock sub menu. Stock ... Nov 7, 2023 · bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. bluebird bio specializes in gene therapies for severe genetic diseases and has 2 FDA-approved products. EV/Sales multiple appears cheap. Find out why BLUE stock is a Buy.On average, Wall Street analysts predict that Bluebird Bio's share price could reach $7.55 by Nov 8, 2024. The average Bluebird Bio stock price prediction ...Latest news about bluebird bio, Inc. Wedbush Lowers bluebird bio's Price Target to $5 From $7, Maintains Neutral Rating. Nov. 08. MT. Transcript : Bluebird bio, Inc., Q3 2023 Earnings Call, Nov 07, 2023. Nov. 07. CI. Earnings Flash (BLUE) BLUEBIRD BIO Reports Q3 Revenue $12.4M, vs. Street Est of $13.4M. Nov. 07.AnaptysBio Inc. 14.20. UNCH. UNCH. Get bluebird bio Inc (BLUE:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

Nov 29, 2023 · Even Bluebird Bio (NASDAQ:BLUE) is waiting on a US FDA decision on its sickle cell treatment, lovo-cel.With a decision date set for Dec. 20, BLUE is already gaining momentum, running from about $2 ... The low in the last 52 weeks of bluebird bio stock was 2.52. According to the current price, bluebird bio is 155.56% away from the 52-week low. What was the 52-week high for bluebird bio stock?Bluebird Bio. Market Cap. $425M. Today's Change. Current Price. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may differ from The Motley Fool’s ...Latest news about bluebird bio, Inc. Wedbush Lowers bluebird bio's Price Target to $5 From $7, Maintains Neutral Rating. Nov. 08. MT. Transcript : Bluebird bio, Inc., Q3 2023 Earnings Call, Nov 07, 2023. Nov. 07. CI. Earnings Flash (BLUE) BLUEBIRD BIO Reports Q3 Revenue $12.4M, vs. Street Est of $13.4M. Nov. 07.Specifically, the biotech's stock is down by 11% as of 12:56 p.m. ET on Monday. Bluebird's shares are retreating today in response to two key issues: First, the company's 2021 fourth-quarter and ...With its shares down by around 84% in the past year, it's a wonder that investors are still interested in Bluebird Bio ( BLUE -4.44%) at all. It withdrew its beta thalassemia drug, Zynteglo, from ...Stock Price Forecast. According to 9 stock analysts, the average 12-month stock price forecast for bluebird bio stock is $7.91, which predicts an increase of 108.71%. The lowest target is $3.00 and the highest is $13. On average, analysts rate bluebird bio stock as a buy.

The market expects Bluebird Bio (BLUE) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2022. This widely-known consensus ...

bluebird bio specializes in gene therapies for severe genetic diseases and has 2 FDA-approved products. EV/Sales multiple appears cheap. Find out why BLUE stock is a Buy.Earnings for bluebird bio are expected to decrease in the coming year, from ($1.81) to ($1.84) per share. bluebird bio has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 3rd, 2024 based off prior year's report dates. Read [email protected]. Investor Contacts. Courtney O’Leary. Investor Relations (978) 621-7347. [email protected]. stock quote stock sub menu. Stock ... What happened. Shares of the gene therapy pioneer Bluebird Bio ( BLUE -1.04%) have been under heavy pressure this week. The biotech's stock dropped by a noteworthy 28.8% during the first three and ...Bluebird Bio has a market capitalization of around $425 million at the moment, so this small-cap biotech stock could see a significant increase in its share …SOMERVILLE, Mass., January 19, 2023--bluebird bio, Inc. (Nasdaq: BLUE) ("bluebird") today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a ...

[relinking] Home History Owners Mission How It Works How It Makes Money A Brief History of bluebird bio, Inc. (BLUE) bluebird bio, Inc. is a biotechnology company that focuses on developing gene therapies for severe genetic diseases and cancer. The company was founded in 1992 by a group of former employees of Genzyme, a biotechnology company …

Historical daily share price chart and data for Bluebird Bio since 2013 adjusted for splits and dividends. The latest closing stock price for Bluebird Bio ...

Overview Corporate Governance Press Releases Events & Presentations Analyst Coverage Stock Information SEC Filings Investor FAQs Toolkit Annual Meeting …The high in the last 52 weeks of bluebird bio stock was 8.58. According to the current price, bluebird bio is 50.47% away from the 52-week high. What are analysts …According to 9 stock analysts, the average 12-month stock price forecast for bluebird bio stock is $7.91, which predicts an increase of 107.07%. The lowest target is $3.00 and the highest is $13. On average, analysts rate bluebird bio stock as a buy.bluebird bio, Inc., based in Somerville, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders. The company's only - in the European Union (EU) - approved drug is betibeglogene autotemcel (Zynteglo), which treats transfusion-dependent beta thalassemia (TDT), a rare genetic blood disorder, and has been approved for use by the European Medicines Agency. Comprehensive suite of tools for trading and investing in biotech stocks. FDA Calendar, PDUFA Date Calendar, Biotech Company Screener and Database and much moreAnaptysBio Inc. 14.20. UNCH. UNCH. Get bluebird bio Inc (BLUE:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Shares of Bluebird Bio ( BLUE 2.64%) were plunging 19.3% lower as of 3:42 p.m. EST on Monday. The sharp decline came after two analysts downgraded Bluebird. Goldman Sachs ( GS 0.15%) analyst ...The high in the last 52 weeks of bluebird bio stock was 8.58. According to the current price, bluebird bio is 50.47% away from the 52-week high. What are analysts …A high-level overview of 2seventy bio, Inc. (TSVT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.1h. Shares of bluebird bio BLUE have increased by 25.6% in a month compared with the industry’s growth of 0.2%. Last month, bluebird posted better-than-expected results in the third quarter. It ...The company’s stock opened at $2.4 and closed at $2.2, a drop of 6.4% from the prior closing price of $2.4. This price decline follows a string of positive news for the company, including a strong second quarter performance …

On average, Wall Street analysts predict. that Bluebird Bio's share price could reach $7.64 by Nov 8, 2024. The average Bluebird Bio stock price prediction forecasts a potential upside of 96.45% from the current BLUE share price of $3.89.http://www.bluebirdbio.com. External link for bluebird bio. Industry: Biotechnology ... Stock. BLUE. December 2, 2023. NASDAQ. 20 minutes delay. $4.26. 0.44 ( ...Shares of this under-the-radar cell therapy stock are set to double, says Baird. Published Tue, Mar 7 202312:39 PM EST Updated Tue, Mar 7 20231:46 PM EST. Michelle Fox @MFoxCNBC.bluebird bio Stock Up 11.5 % NASDAQ BLUE traded up $0.44 during trading on Friday, reaching $4.26. 5,100,895 shares of the stock traded hands, compared to its average volume of 4,113,761.Instagram:https://instagram. best financial advisors in rhode islandiso20022 coinautographed tom brady rookie cardamzn stock prediction 2025 Bluebird bio Inc () Stock Market info Recommendations: Buy or sell Bluebird bio stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Bluebird bio share forecasts, stock quote and buy / sell signals below.According to present data Bluebird bio's BLUE shares and potentially its market environment have been in bearish … best short term health insurance virginiabest investment mortgages 04:04 PM ET 08/09/2021. Bluebird Bio ( BLUE) said Monday the Food and Drug Administration paused one of its gene therapy studies due to safety concerns, and BLUE stock collapsed. The drug isn't ... service now share price Dec 1, 2023 · Who is on bluebird bio's Insider Roster? The list of insiders at bluebird bio includes Alison Cecily Finger, Andrew Obenshain, Anne-Virginie Eggimann, Jason Cole, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Nick Leschly, Richard A Colvin, Thomas J Klima, and William D Baird III. Learn more on insiders at BLUE. Let's look at Bluebird Bio (BLUE 2.64%). Per Wall Street's analysts, its shares could rise 118% by this time next year despite losing 51% of their value so far in 2023.